|Dr. Michael D. West||Co-CEO & Director||758.57k||N/A||1953|
|Mr. Aditya P. Mohanty||Co-CEO, Pres & Director||763.25k||N/A||1967|
|Mr. Russell L. Skibsted||Chief Financial Officer||493.25k||N/A||1959|
|Mr. Dan L. Lawrence||Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Dr. Stephana E. Patton Ph.D., J.D.||Gen. Counsel and Corp. Sec.||N/A||N/A||1971|
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. BioTime, Inc. was founded in 1990 and is based in Alameda, California.
BioTime, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 5. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 3; Compensation: 7.